Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - dalfampridine - prolonged-release tablet - 10 mg

European Union - English - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - hiv infections - antivirals for systemic use - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium; rilpivirine as hydrochloride - film coated tablets - rilpivirine as hydrochloride 25 mg; dolutegravir as sodium 50 mg - dolutegravir and rilpivirine - juluca is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor

European Union - English - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv infections - antivirals for systemic use - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

European Union - English - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, rilpivirine hydrochloride - hiv infections - antivirals for systemic use - juluca is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna

European Union - English - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine - hiv infections - antivirals for systemic use - dovato is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 10 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 25 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 50 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children above 6 years of age.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 50 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.